Revagenix, Inc. Announces Series B Financing to Develop Novel Antibiotics and Additions to its Board of Directors

Tenmile and Novo Holdings are core investors
Cristina Larkin, Bruce Montgomery, and Michael Lamprecht to join the Board of Directors
Revagenix, Inc. is advancing a focused pipeline of antibiotic programs designed to treat infections caused by multidrug-resistant organisms

SAN FRANCISCO, Jan. 5, 2024 – Revagenix, Inc., a biopharmaceutical company dedicated to the discovery and development of novel antibiotics, today announced the appointment of Cristina Larkin, Bruce Montgomery, MD, and Michael Lamprecht, PhD, to its board of directors in conjunction with closing its Series B funding round from core investors Tenmile and Novo Holdings. Ryan Cirz, PhD, Chief Executive Officer and director, highlighted these developments as important milestones in the growth of the Company that will enable its mission of creating life-changing antibiotics through scientific innovation and strategic leadership.

Locations